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Abstract 
 
For the development of efficient pulmonary delivery systems for protein and peptide 
drugs, it is important to understand their transport mechanisms in alveolar epithelial 
cells. In this study, the uptake mechanism for FITC-insulin in cultured alveolar 
epithelial cell line RLE-6TN was elucidated. FITC-insulin uptake by RLE-6TN cells 
was time-dependent, temperature-sensitive, and concentration-dependent. The uptake 
was inhibited by metabolic inhibitors, cytochalasin D, clathrin-mediated endocytosis 
inhibitors, and dynasore, an inhibitor of dynamin GTPase. On the other hand, no 
inhibitory effect was observed with caveolae-mediated endocytosis inhibitors and a 
macropinocytosis inhibitor. Intracellular FITC-insulin was found to be partly 
transported to the basal side of the epithelial cell monolayers. In addition, colocalization 
of FITC-insulin and LysoTracker Red was observed on confocal laser scanning 
microscopy, indicating that FITC-insulin was partly targeted to lysosomes. In 
accordance with these findings, SDS-PAGE/fluoroimage analysis showed that intact 
FITC-insulin in the cells was eliminated with time. The possible receptor involved in 
FITC-insulin uptake by RLE-6TN cells was examined by using siRNA. Transfection of 
the cells with megalin or insulin receptor siRNA successfully reduced the corresponding 
mRNA expression. FITC-insulin uptake decreased on the transfection with insulin 
receptor siRNA, but not that with megalin siRNA. These results suggest that insulin is 
taken up through endocytosis in RLE-6TN cells, and after the endocytosis, the 
intracellular insulin is partly degraded in lysosomes and partly transported to the basal 
side. Insulin receptor, but not megalin, may be involved at least partly in insulin 
endocytosis in RLE-6TN cells. 
 
Keywords: Alveolar epithelial cells; Insulin; Endocytosis; Dynamin; Megalin; Insulin 
receptor 
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1. Introduction 
 
The lung is important as a possible administration route for drugs because of its 
large alveolar surface area and extremely thin epithelial barrier (Colthorpe et al., 1992). 
These structural features would be advantageous for the absorption of small, lipophilic 
drugs through a passive diffusion, but not to the absorption of protein and peptide drugs 
of large molecular sizes. 
The alveolar region of the lung is lined with a continuous epithelium comprising 
type I and type II epithelial cells. Squamous type I cells cover 90 - 95% and cuboidal 
type II cells cover 5 - 10% of the alveolar surface area, though the number of type II 
cells is greater than that of type I cells (Kim and Malik, 2003). Using primary cultured 
alveolar epithelial cells, we previously reported that the uptake clearance of albumin 
was much greater in type II than in type I cells. Assuming that the number of type II 
cells is about 1.5-fold of that of type I cells, the contribution of type II cells to total 
albumin uptake was estimated to be more than 75% (Ikehata et al., 2008). Similarly, the 
contribution of type II cells to total insulin uptake was estimated to be more than 50% 
(Ikehata et al., 2009). Thus, though the surface area occupied by type II cells is quite 
small, type II cells may play an important role in the uptake of protein and peptide drugs 
in the lung. 
The mechanisms for the clearance of various proteins and peptides from the alveolar 
space have been widely studied, and among the mechanisms proposed, endocytosis 
(transcytosis) is probably the most important (Hastings et al., 2004; Kim and Malik, 
2003). Though a primary culture is a good experimental system, it is not suitable for an 
experiment involving a long-time treatment such as siRNA study, because type II cells 
in primary culture transdifferentiate into type I-like cells with time. Therefore, an 
established cell line would be an alternative and a useful experimental system for 
studying the alveolar transport of drugs. RLE-6TN cells have several characteristics 
similar to alveolar type II epithelial cells (Driscoll et al., 1995), and we have utilized 
RLE-6TN cells to clarify the transport mechanism for albumin (Yumoto et al., 2006). 
Insulin is an important therapeutic drug for the treatment of diabetes mellitus. 
Recently, the lung has attracted a great deal of interest as an alternative administration 
route, and clinical research has confirmed the efficacy and safety of inhaled insulin in 
the treatment of diabetes mellitus (Agu et al., 2001; Galan et al., 2006; Scheuch et al., 
2006). Unfortunately, inhaled insulin (Exbera
®
) has been withdrawn from the market, 
predominantly because of its low bioavailability and high cost (Siekmeier and Scheuch, 
2008). However, information concerning insulin transport in alveolar epithelial cells is 
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still lacking, and understanding of its mechanisms may facilitate the development of 
more efficient form of inhaled insulin in the future. In this study, the mechanisms 
underlying insulin uptake and the fate of intracellular insulin were examined in 
RLE-6TN cells. 
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2. Materials and methods   
 
2.1. Materials   
 
Dulbecco’s Modified Eagle’s medium: Nutrient Mixture F-12 (Ham) (1:1) 
(DMEM/F-12), trypsin-EDTA, penicillin-streptomycin, Lipofectamine
TM
 2000, 
LysoTracker
®
 Red DND-99 (LysoTracker Red) as a fluorescent lysosomal marker, and 
rat megalin siRNA were purchased from Invitrogen (Grand Island, NY, USA). Fetal 
bovine serum (FBS) was purchased from Biological Industries Ltd. (Kibbutz Beit 
Haemek, ISRAEL). Fluorescein isothiocyanate-labeled insulin from bovine pancreas 
(FITC-insulin), phenylarsine oxide (PAO), indomethacin (IND), nystatin (NYS), 
5-(N-ethyl-N-isopropyl) amiloride (EIPA), and cytochalasin D (Cyto D) were 
purchased from Sigma-Aldrich (St. Louis, MO, USA). Chlorpromazine (CPZ) and 
2,4-dinitrophenol (DNP) were purchased from Nacalai Tesque (Kyoto, Japan). 
2-Deoxy-D-glucose (2DOG) was purchased from Kanto Chemical Co. (Tokyo, Japan) 
and sodium azide (NaN3) from Katayama Chem. (Tokyo, Japan). Hoechst 33342 
solution as a fluorescent nucleus marker, and HilyMax were purchased from Wako Pure 
Chemical Ind. (Osaka, Japan). ReverTra Ace and SYBR Green were from TOYOBO 
(Osaka, Japan). Rat insulin receptor siRNA was purchased from Santa Cruz 
Biotechnology (Santa Cruz, CA, USA). [
3
H]Gentamicin sulfate (7.4 GBq/g) was 
obtained from American Radiolabeled Chemicals (St. Louis, MO, USA). All other 
chemicals used for the experiments were of the highest purity commercially available.  
 
2.2. Cell culture  
 
RLE-6TN cells were obtained from the American Type Culture Collection (ATCC 
no. CRL-2300; Manassas, VA, USA) and were cultured as described previously 
(Tagawa et al., 2008; Yumoto et al., 2006). The cells were used for the experiments on 
the seventh day after seeding between passages 48 and 65.  
 
2.3. Uptake of FITC-insulin by RLE-6TN cells 
 
Uptake experiments were performed as described previously (Ikehata et al., 2009; 
Tagawa et al., 2008; Takano et al., 2002). Briefly, RLE-6TN cells grown on 35-mm 
culture dishes were used. After removal of the culture medium, each dish was washed 
and preincubated with phosphate-buffered saline (137 mM NaCl, 3 mM KCl, 8 mM 
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Na2HPO4, 1.5 mM KH2PO4, 0.1 mM CaCl2, and 0.5 mM MgCl2, pH 7.4) (PBS buffer) 
supplemented with 5 mM D-glucose (PBS-G buffer) at 37C for 10 min. Then, PBS-G 
buffer containing FITC-insulin (20 g/ml) was added to each dish, and the cells were 
incubated at 37C or 4C for a specified period. 
In the case of the concentration-dependence of insulin uptake, unlabeled insulin was 
dissolved in 0.1 M HCl, and then diluted with potassium free phosphate-buffered saline 
(137 mM NaCl, 8 mM Na2HPO4, 2 mM NaH2PO4, 0.1 mM CaCl2, and 0.5 mM MgCl2, 
pH 7.4) supplemented with 5 mM D-glucose (K
+
 free PBS-G buffer). The pH of the 
solution was adjusted to 7.4 with 0.1 M NaOH. The kinetic parameters of insulin uptake 
were determined using the following Michaelis-Menten equation; V = Vmax ∙ Cγ ∕ (Kmγ 
+ C
γ
), where V is the uptake rate of insulin (g/mg protein/60 min), C is the 
concentration of insulin, Vmax is the maximal uptake rate, Km is the apparent 
Michaelis constant, and γ is the Hill coefficient. The nonlinear curve was fitted with the 
KaleidaGraph program. 
For inhibition studies, RLE-6TN cells were preincubated with PBS or PBS-G buffer 
at 37C or 4C with or without an inhibitor as follows; 1 mM DNP and 10 mM NaN3 
plus 5 mM 2DOG for 10 min in PBS buffer, 300 M IND and 50 M CPZ for 10 min 
in PBS-G buffer, 50 M NYS, 5 M PAO and 10 - 60 M dynasore for 10 min, 40 M 
Cyto D for 15 min, and 50 M EIPA for 30 min in PBS-G buffer containing 0.5% 
DMSO. The same vehicle was used for each control experiment. Then, the cells were 
incubated with 1 ml of the buffer containing FITC-insulin with or without (control) an 
inhibitor at 37C or 4C for a specified period. PAO was only used in the preincubation 
buffer and was not added to the uptake buffer. 
At the end of the incubation, the cells were rinsed three times with ice-cold PBS 
buffer or K
+
-free PBS buffer (for the study of concentration-dependent insulin uptake) 
followed by scraping with a rubber policeman. Then, the cells were washed with PBS or 
K
+
-free PBS buffer by centrifugation at 9838 g for 3 min at 4 °C twice, and the final 
pellet was solubilized in 0.1% Triton X-100 in PBS buffer without CaCl2 and MgCl2 for 
30 min at room temperature, followed by centrifugation at 5600 g for 3 min. The 
supernatant was used for fluorescence and protein assays. The fluorescence of 
FITC-insulin was measured using a Hitachi fluorescence spectrophotometer F-3000 
(TOKYO, Japan) at excitation and emission wavelengths of 500 and 520 nm, 
respectively. Protein contents were determined by the Lowry method with bovine serum 
albumin as the standard. 
 
2.4. Transport of intracellular FITC-insulin to the basal side of the epithelial 
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monolayers 
 
RLE-6TN cells were seeded at 80,000 cells/cm
2
 on Transwell inserts (24 mm 
diameter inserts, 0.4 m pore size, Corning Incorporated, NY, USA) and cultured for 10 
days. To measure the transport of intracellular FITC-insulin to the basal side of the 
epithelial monolayers, cells grown on Transwell inserts were incubated with 
FITC-insulin (200 g/mL) for 60 min. After washing, the cells were incubated with 
fresh PBS-G buffer without FITC-insulin at 37C for a specified period. Remaining 
amount of FITC-insulin in the cells and transported amount of FITC-insulin from the 
cells to the basal side were measured using a fluorescence spectrophotometer.  
 
2.5. Confocal laser scanning microscopy   
 
RLE-6TN cells were grown on 35-mm glass-bottom culture dishes for 5 days. The 
cells were incubated with FITC-insulin (20 g/ml), LysoTracker Red (75 nM), and 
Hoechst 33342 (10 M) for 30 min at 37C or 4C, and after washing the cells with 
ice-cold PBS buffer three times for 5 min each, the fluorescence in the cells was 
visualized by confocal laser scanning microscopy (LSM5 Pascal, Carl ZEISS, 
Germany).  
 
2.6. Pulse-chase analysis of intact FITC-insulin in RLE-6TN cells 
 
To evaluate the intactness of FITC-insulin in RLE-6TN cells, the cells were 
incubated with FITC-insulin for 60 min at 37C, and after washing, the cells were 
further incubated with PBS-G buffer without FITC-insulin for 30, 60, or 90 min at 37C. 
The cell samples were solubilized in a loading buffer consisting of 2% SDS, 50 mM 
Tris-HCl, and 10% glycerol. Then, each sample was subjected to SDS-polyacrylamide 
gel electrophoresis (PAGE) on 15% polyacrylamide gels. After the SDS-PAGE, the 
fluorescence intensity of the gel was analyzed with a fluoroimage analyzer FLA-2000 
(Fuji Photo Film, Tokyo, Japan). 
 
2.7. Transfection with siRNAs, and uptake studies on FITC-insulin and [
3
H]gentamicin 
 
RLE-6TN cells were seeded at a density of 18 x 10
4
 cells/well on 12-well plates or 8 
x 10
4
 cells/well on 24-well plates. After 24 hr, cells were transfected with a 
megalin-specific siRNA using HilyMax or an insulin receptor-specific siRNA using 
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Lipofectamine
TM 
2000, according to the manufacturer’s instructions. The sequences of 
the megalin siRNAs were: sense, GCUAUUGUAUUAGAUCCUUtt and anti-sense, 
AAGGAUCUAAUACAAUAGCtt. Non-targeting siRNA was used as a control in an 
identical manner. Briefly, cells were transfected with siRNA (100 nM) complexed with 
HilyMax (6 l/ml) or LipofectamineTM 2000 (2 l/ml) for 24 hr. After 48 hr, the 
efficiency of siRNA silencing was evaluated by Western blot and real-time PCR 
analyses, and uptake study was performed as described in section 2.3. In the case of 
[
3
H]gentamicin, the cells were solubilized in 0.1 M NaOH, and then the amount of 
substrate taken up by the cells was measured by counting the radioactivity. Protein 
contents were determined by the Bradford method. 
 
2.8. RT-PCR analysis of insulin receptor mRNA expression in RLE-6TN cells and 
primary cultured rat alveolar type II epithelial cells 
 
Rat alveolar type II epithelial (AT II) cells were isolated from Sprague-Dawley male 
rats as described previously (Ikehata et al., 2008, 2009). Total RNA was extracted from 
RLE-6TN cells and AT II cells using an RNeasy Mini kit (Qiagen, Valencia, CA, USA), 
and RT-PCR was performed as described previously (Takano et al., 2009). The primers 
were: sense, 5’- ATGGGACCACTGTACGCTTC -3’ and antisense, 5’- 
CATTGAGGAACTCGATCCGT -3’ for insulin receptor (expected size of PCR product, 
275 bp). The PCR products were separated by electrophoresis on 2.0% agarose gels. 
 
2.9. Real-time PCR analysis 
 
Total RNA (0.8 g), in a final volume of 20 l, was reverse transcribed into cDNA 
using ReverTra Ace. Real-time PCR was performed on a BioFlux LineGene system 
(TOYOBO, Osaka, Japan) using SYBR Green. The PCR conditions were: initial 
denaturation in one cycle of 1 min at 95C, followed by 40 cycles of 5 sec at 95C 
(denaturation), 5 sec at 60C (annealing), and 15 sec at 72C (extension). The primers 
were: sense, 5’-AAAGTGGCCCTGGCAGTTC-3’ and antisense, 
5’-GAAGGATCTATGGGCCTTCCA-3’ for megalin; sense, 
5’-CGTCATTCACAACAACAAGTG-3’ and antisense, 
5’-ATGGTCTTCTCGCCTTCG-3’ for insulin receptor; and sense, 
5’-AGCCCAGAACATCATCCCTG-3’ and antisense, 
5’-CACCACCTTCTTGATGTCATC-3’ for GAPDH. The expression level of each 
mRNA was normalized as to that of GAPDH, a house-keeping gene. 
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2.10. Western blot analysis 
 
The amount of megalin in RLE-6TN cells was determined by Western blot analysis 
as described previously (Nagai et al., 2001). Proteins were extracted from the cells using 
cell lysis buffer comprising 150 mM NaCl, 5mM EDTA, 1mM PMSF, 10 mM Tris, 1% 
Triton-X100, 0.1% SDS, and 1% sodium deoxycholate (pH 7.4). The lysates were 
centrifuged at 8,720 g for 5 min at 4C and the supernatants were stored at - 80C. 8 g 
protein extracts were subjected to SDS-PAGE on 6% polyacrylamide gels, and then 
transferred to polyvinylidene difuluoride (PVDF) membranes. After blotting, the 
membranes were blocked with 0.5% skim milk and subsequently incubated with anti-rat 
megalin rabbit anti-serum (1:1000 dilution). The membranes were washed three times 
in TBS-T (20.5 mM Tris, 150 mM NaCl, 0.05% Tween20, pH 7.5), and then incubated 
with horseradish peroxidase-conjugated anti rabbit IgG antibodies (1:2000 dilution). 
After washing three times in TBS-T, the antibody complexes were visualized with 
Amersham ECL Plus Detection reagents. The blocking and antibody incubation 
processes were performed by use of an SNAP i.d. system (Millipore, Billerica, MA, 
USA). The optical densities of immunoreactive proteins were determined with a 
computer-aided densitometer with NIH Image (the public domain program developed at 
the U.S. National Institutes of Health, Bethesda, MD, USA). 
 
2.11. Statistical analysis   
 
All data were expressed as means ± standard error of the mean (S.E.M.). Statistical 
analysis was performed by the Student‘s t-test or one-way ANOVA, followed by the 
Tukey-Kramer’s test for multiple comparisons. The level of significance was set at 
*P<0.05 or ** P<0.01. 
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3. Results 
 
3.1. General characteristics of FITC-insulin uptake by RLE-6TN cells 
 
In order to understand the general characteristics of FITC-insulin uptake by 
RLE-6TN cells, the time- and temperature-dependence of FITC-insulin uptake were 
measured (Fig. 1A). FITC-insulin was taken up by the cells at 37C, and the uptake 
increased with time for up to 60 min. The apparent uptake at 4C, probably reflecting 
cell surface binding, was also time-dependent, but was significantly lower than that at 
37C. Next, the uptake of insulin in 60 min was measured in the concentration range of 
20-2000 g/ml at 37C. As shown in Fig. 1B, insulin uptake by RLE-6TN cells showed 
a sigmoid curve (Hill coefficient, 1.2) and saturation kinetics. The apparent Michaelis 
constant (Km) and maximum uptake rate (Vmax) were calculated to be 1892 g/ml and 
208.3 g/mg protein/60 min, respectively. In the following uptake experiments, the 
amount of FITC-insulin taken up into the cells (specific uptake) was determined by 
subtracting the cell surface binding at 4C from the total cell association at 37C.   
 
3.2. Endocytic pathway for FITC-insulin 
 
The effects of metabolic inhibitors on FITC-insulin uptake by RLE-6TN cells were 
examined. Treatment of the cells with NaN3 plus 2DOG or DNP significantly inhibited 
FITC-insulin uptake (Fig. 2A). We then examined the effects of various endocytosis 
inhibitors on FITC-insulin uptake. Cyto D, an F-actin polymerization inhibitor, 
inhibited the FITC-insulin uptake. PAO and CPZ, clathrin-mediated endocytosis 
inhibitors, also inhibited FITC-insulin uptake, though the extents of inhibition were 
fairly low. On the other hand, no inhibitory effect was observed on treatment with NYS 
and IND, caveolae-mediated endocytosis inhibitors, or on the treatment with EIPA, a 
macropinocytosis inhibitor. Furthermore, the effect of dynasore, a dynamin GTPase 
inhibitor, on FITC-insulin uptake by RLE-6TN cells was examined (Fig. 2B). 
FITC-insulin uptake was inhibited by dynasore in a concentration-dependent manner. 
 
3.3. Transport of intracellular FITC-insulin to the basal side of the epithelial 
monolayers 
 
In order to characterize the transport of intracellular FITC-insulin to the basal side 
of epithelial monolayers, RLE-6TN cells grown in a Transwell chamber were used. We 
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first attempted to quantitate the transcellular transport of FITC-insulin, but RLE-6TN 
cell monolayers in the Transwell chamber were so leaky that FITC-insulin was 
predominantly transported from the apical side to the basal side via a paracellular route. 
In fact, the TEER values obtained for these monolayers were much lower than those 
reported for the alveolar epithelium in the lung, being around 100 - 170 Ω･cm2 even at 
10 days after seeding. Under these conditions, the paracellular transport was too high to 
quantitate transcellular transport (transcytosis) properly. Therefore, in order to 
quantitate transcytosis of FITC-insulin, the efflux of FITC-insulin preloaded into the 
cells to the basal side was measured. Intracellular FITC-insulin was gradually 
transported to the basal side (Fig. 3A). As shown in Fig. 3B, SDS-PAGE/fluoroimage 
analysis revealed that most of the FITC-insulin transported to the basal side was intact. 
In accordance with the efflux of FITC-insulin, the amount of FITC-insulin remaining in 
the cells decreased after 2.5 hr incubation with PBS-G buffer (Fig. 3C).  
 
3.4. Intracellular localization of FITC-insulin taken up by RLE-6TN cells 
 
Intracellular localization of FITC-insulin was examined by confocal laser scanning 
microscopy. When RLE-6TN cells were incubated with FITC-insulin at 37
o
C, punctate 
localization of fluorescence was observed in the cells (Fig. 4A). On the other hand, 
when the cells were incubated with FITC-insulin at 4
o
C, intracellular localization of 
FITC-insulin was not observed (Fig. 4D). Figure 4B shows the fluorescence of 
LysoTracker Red, a lysosomal marker, simultaneously added to the uptake buffer with 
FITC-insulin at 37
o
C. As shown in Figure 4C, colocalization of FITC-insulin and 
LysoTracker Red was observed at 37
o
C, indicating that part of the FITC-insulin taken 
up by the cells was targeted to lysosomes. 
 
3.5. Degradation and elimination of intracellular FITC-insulin after being taken up by 
RLE-6TN cells 
 
The intactness of FITC-insulin in cells was evaluated with a fluoroimage analyzer 
after SDS-PAGE (Fig. 5A). Figure 5B shows the results of pulse-chase analysis, the 
FITC-insulin taken up by RLE-6TN cells being gradually degraded/eliminated over 
time. Using semilogarithmic plots (Fig. 5C), the half-life of FITC-insulin in the cells 
was calculated to be 77 min.  
 
3.6. siRNA transfection study 
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   Megalin is a candidate receptor for insulin (Orlando et al., 1998). Therefore, we first 
attempted to clarify the role of megalin in FITC-insulin uptake by RLE-6TN cells by 
transfection with megalin siRNA. Transfection of cells with megalin-specific siRNA 
reduced the mRNA expression level (Fig. 6A) and the protein expression level (Fig. 6B) 
of megalin. Using these megalin knockdown cells, the uptake of [
3
H]gentamicin, which 
is well known to be a megalin ligand (Moestrup et al., 1995), and FITC-insulin were 
examined. As shown in Fig. 7A, the uptake of [
3
H]gentamicin was significantly reduced 
in RLE-6TN cells transfected with megalin-specific siRNA compared with those 
transfected with nonspecific (control) siRNA. In contrast, FITC-insulin uptake was not 
affected by transfection with megalin siRNA (Fig. 7B). 
Next, we examined the role of insulin receptor in FITC-insulin uptake by using 
insulin receptor siRNA. The mRNA expression of insulin receptor was confirmed by 
RT-PCR in RLE-6TN cells as well as in primary cultured type II epithelial cells (Fig. 
8A). Transfection of RLE-6TN cells with the siRNA significantly reduced the mRNA 
expression of insulin receptor. The uptake of FITC-insulin was significantly reduced in 
the RLE-6TN cells transfected with insulin receptor siRNA compared with those 
transfected with control siRNA. 
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4. Discussion  
 
We first examined the general characteristics of FITC-insulin uptake by rat alveolar 
type II epithelial cell line, RLE-6TN. The uptake of FITC-insulin was time- and 
temperature-dependent (Fig. 1A), and showed saturation kinetics (Fig. 1B). Metabolic 
inhibitors potently inhibited the FITC-insulin specific uptake (temperature-sensitive 
uptake). In addition, an inhibitory effect of Cyto D, which is known to inhibit F-actin 
polymerization and therefore inhibit various endocytic processes, on FITC-insulin 
uptake was observed (Fig. 2). These results indicate that energy-dependent, saturable 
mechanism, most likely receptor-mediated endocytosis, is involved in FITC-insulin 
uptake by RLE-6TN cells. These characteristics are essentially the same as those 
observed for primary cultured alveolar type II epithelial cells (Ikehata et al., 2009), 
though the apparent affinity seems to be somewhat lower in RLE-6TN cells. 
There are numerous ways that endocytic cargo molecules are internalized from the 
surface of eukaryotic cells (Mayor and Pagono, 2007). Endocytic pathways are divided 
into at least four mechanisms; clathrin-mediated endocytosis, caveolae-mediated 
endocytosis, macropinocytosis and other types of endocytosis (clathrin- and 
caveolae-independent endocytosis). Clathrin-mediated endocytosis, which is the best 
characterized endocytosis pathway, involves many proteins such as clathrin and 
assembly protein (AP) 2. Caveolae-mediated endocytosis occurs through flask-shaped 
invaginations of the plasma membrane, and the involvement of intracellular protein 
caveolin-1 is known. In addition, dynamin, which is a large GTPase and functions in 
membrane tubulation and fission of budding vesiculo-tubular structures, is necessary for 
both clathrin- and caveolae-mediated endocytosis. Macropinocytosis accompanies the 
membrane ruffling that is induced in many types of cells upon stimulation by growth 
factors or other signals. Macropinocytosis generates relatively large vesicles (1 - 5 m) 
that are associated with the formation of actin-dependent membrane ruffles. In alveolar 
epithelial cells, the endocytic pathway for insulin is unclear. Therefore, we further 
investigated the uptake mechanism for FITC-insulin focusing on three types of 
endocytosis; clathrin-mediated endocytosis, caveolae-mediated endocytosis and 
macropinocytosis. 
PAO inhibits clathrin-mediated endocytosis by reacting with vicinal sulfhydryls to 
form stable ring structures (Visser et al., 2004). CPZ inhibits the process by inducing 
the loss of coated pits from the cell surface, probably by interacting with AP2 binding to 
membranes (Wang et al., 1993). In this study, both compounds slightly inhibited 
FITC-insulin uptake by RLE-6TN cells. We previously showed that FITC-albumin 
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uptake was inhibited by PAO and CPZ, and suggested the involvement of 
clathrin-mediated endocytosis in RLE-6TN cells (Yumoto et al., 2006). However, the 
extents of inhibition by these inhibitors were quite different between FITC-albumin and 
FITC-insulin uptake by RLE-6TN cells. FITC-albumin uptake was much more potently 
inhibited by PAO and CPZ (by 60 - 70%) than FITC-insulin uptake (by 18 - 20%). In 
addition, we recently reported that in primary cultured rat alveolar type II epithelial cells, 
the inhibition of FITC-insulin uptake by PAO and CPZ was not high (by 7 - 13%), and 
was statistically insignificant (Ikehata et al., 2009). Thus, clathrin-mediated endocytosis 
may be involved in FITC-insulin uptake by RLE-6TN cells, but its contribution may not 
be so high in alveolar type II epithelial cells. Another endocytosis inhibitor, dynasore, 
inhibited FITC-insulin uptake by RLE-6TN cells. The sensitivity of FITC-insulin 
uptake to dynasore in RLE-6TN cells was similar to that observed in primary cultured 
type II cells (Ikehata et al., 2009). 
NYS and IND were used as inhibitors of caveolae-mediated endocytosis. NYS 
inhibits caveolae-mediated endocytosis by interacting with cholesterol in the plasma 
membrane (Sieczkarski and Whittaker, 2002), and IND inhibits the process by 
inhibiting the internalization of caveolae and the return of plasmalemmal vesicles to the 
cell surface (Smart et al., 1995). In fact, on confocal laser scanning microscopic analysis, 
we previously observed that the uptake of cholera toxin subunit B, which is a marker of 
caveolae-mediated endocytosis, was potently blocked by NYS and IND in RLE-6TN 
cells (Takano and Yumoto, 2011), indicating that the caveolae-mediated endocytosis 
pathway was functioning in RLE-6TN cells. However, the FITC-insulin uptake by 
RLE-6TN cells was not affected by these inhibitors (Fig. 2). Xu et al. (1996) reported 
that insulin enhanced macropinocytosis through insulin receptor activation in Chinese 
hamster ovary cells transfected with human insulin receptor. However, in this study, no 
inhibitory effect on FITC-insulin uptake was observed on treatment with EIPA, which 
inhibits Na
+
/H
+
 exchanger in the plasma membrane and inhibits macropinocytosis (Fig. 
2). Therefore, neither caveolae-mediated endocytosis nor macropinocytosis would be 
involved in FITC-insulin uptake by RLE-6TN cells. The insensitivity of FITC-insulin 
uptake to the inhibitors of caveolae-mediated endocytosis in RLE-6TN cells was also 
similar to that observed in primary cultured type II cells (Ikehata et al., 2009). 
Additional pathways, which are energy-dependent but clathrin-, caveolae-, and 
macropinocytosis-independent, may be involved in FITC-insulin uptake by RLE-6TN 
cells. 
As described above, FITC-insulin uptake by RLE-6TN cells was inhibited by 
dynasore, an inhibitor of a large GTPase dynamin. According to the classification of 
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endocytic pathways by Mayor and Pagano (2007), several endocytic pathways that are 
not associated with clathrin and caveolae are emerging. One of such pathways is 
dynamin-dependent, RhoA-regulated pathway. RhoA is a small GTPase, and has been 
found to regulate the internalization of β-chain of the interleukin-2 receptor; thus it is 
also called IL2R pathway (Doherty and McMahon, 2009; Lamaze et al., 2001). Based 
on the above classification and the present results, FITC-insulin uptake may partly be 
mediated by clathrin- and caveolae-independent, but dynamin-dependent, 
RhoA-regulated pathway in RLE-6TN cells as well as in primary cultured alveolar type 
II epithelial cells. 
In order to study the fate of FITC-insulin taken up by RLE-6TN cells, transport of 
FITC-insulin from the cells to the basal side of epithelial monolayers was examined 
using a Transwell chamber (Fig. 3). Intracellular FITC-insulin was gradually 
transported to the basal side mostly as an intact form. Some reports have suggested that 
inhaled insulin is transported across the alveolar epithelial barrier through passive 
diffusion (Bur et al., 2006). In contrast, our results may indicate that inhaled insulin is 
absorbed from the lung, at least in part, through transcytosis. Next, intracellular 
localization of FITC-insulin in RLE-6TN cells was evaluated by confocal laser scanning 
microscopy (Fig. 4). At 37
o
C, punctate localization of FITC-insulin fluorescence was 
observed in the cells, supporting endocytic uptake of FITC-insulin. On the other hand, 
no fluorescence of FITC-insulin was observed at 4
o
C. Thus, the apparent uptake 
observed at 4C in Fig. 1 would reflect cell surface binding of FITC-insulin, as 
described above. In addition, it was suggested that part of the FITC-insulin taken up by 
the cells was targeted to lysosomes, as evidenced by the colocalization of FITC-insulin 
and LysoTracker Red. In accordance with these results, pulse-chase analysis with an 
SDS-PAGE/fluoroimage analyzer showed that intracellular FITC-insulin was gradually 
degraded and/or eliminated over time, probably due to the degradation in lysosomes and 
efflux from the cells. 
The receptor involved in insulin endocytosis by alveolar epithelial cells is not clear 
at present. Recently, several possible receptors for insulin endocytosis in various types 
of cells have been reported, including megalin and insulin receptor (Guglielmo et al., 
1998; Orlando et al., 1998). Megalin is a large glycoprotein (approximately 600 kDa) 
that functions as an endocytic receptor for multiple ligands including lysozyme, 
cytochrome c, albumin, and aminoglycosides (Christensen and Birn, 2001). The 
receptor belongs to the LDL receptor family, and is highly expressed in renal proximal 
tubule epithelial cells as well as in alveolar type II epithelial cells (Christensen and Birn, 
2001; Kolleck et al., 2002). Using chemical cross-linking and cytochemical procedures, 
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Orlando et al. (1998) obtained potent evidence suggesting that megalin is an endocytic 
receptor for insulin in renal proximal tubules. Therefore, we first investigated the role of 
megalin in insulin endocytosis in RLE-6TN cells. The expression of megalin mRNA 
and protein in RLE-6TN cells was confirmed by real-time PCR and Western blot 
analysis, respectively (Fig. 6). Transfection of RLE-6TN cells with megalin-specific 
siRNA reduced the mRNA and protein expression levels of megalin, and 
[
3
H]gentamicin uptake by the cells. Aminoglycoside antibiotics such as gentamicin are 
well known ligands of megalin, and the predominant role of megalin in the endocytosis 
of aminoglycosides in renal proximal tubular cells has been reported (Nagai et al., 2001; 
Schmitz et al., 2002; Watanabe et al., 2004). Thus, megalin-mediated endocytosis 
would occur in RLE-6TN cells. However, FITC-insulin uptake was not affected by 
transfection with megalin siRNA, indicating that megalin is not involved in insulin 
endocytosis in RLE-6TN cells. 
Insulin receptor is suggested to be responsible for the uptake of insulin into certain 
types of cells (Guglielmo et al., 1998). We also verified the expression of insulin 
receptor mRNA in RLE-6TN cells as well as in primary cultured type II cells by 
RT-PCR analysis (Fig. 8A). Though one report suggested that insulin receptor appeared 
to be localized at the basal side of alveolar epithelial cells (Yamahara et al., 1994), the 
localization of insulin receptor in alveolar epithelial cells remains unclear. Therefore, 
we next examined the role of insulin receptor by using insulin receptor siRNA. 
Transfection of RLE-6TN cells with insulin receptor-specific siRNA successfully 
reduced its mRNA expression level and FITC-insulin uptake. Therefore, insulin 
receptor may be involved at least partly in insulin endocytosis in RLE-6TN cells. The 
involvement of other receptors such as insulin-like growth factor I receptor (IGF-IR), 
which is known to interact with insulin (Chisalita and Arnqvist, 2004), and scavenger 
receptors like SR-AI/II, which can bind to a variety of anionic proteins (Steinbrecher, 
1999), needs to be examined in future. 
In conclusion, FITC-insulin is taken up through endocytosis in alveolar epithelial 
cell line RLE-6TN, and after endocytosis, the intracellular FITC-insulin is partly 
degraded in lysosomes and partly transported to the basal side. Insulin receptor, but not 
megalin, may partly be involved in insulin endocytosis in RLE-6TN cells. These results 
constitute useful information for understanding the uptake mechanism and intracellular 
fate of insulin in alveolar epithelial cells. 
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Figure legends 
Fig. 1. General characteristics of FITC-insulin uptake by RLE-6TN cells. (A) Time- and 
temperature-dependence of FITC-insulin uptake by RLE-6TN cells. The uptake of 
FITC-insulin (20 g/ml) by confluent monolayers of RLE-6TN cells was measured at 
37C (●) or 4C (○). Specific uptake (▲) was estimated by subtracting the cell surface 
binding at 4C from the total cell association at 37C. (B) Concentration-dependence of 
insulin uptake by RLE-6TN cells. The uptake of FITC-insulin (20 g/ml) in the 
presence of various concentrations of unlabeled insulin for 60 min was measured at 
37C. The apparent Michaelis constant (Km), maximum uptake rate (Vmax), and Hill 
coefficient were calculated to be 1892 g/ml, 208.3 g/mg protein/60 min, and 1.2, 
respectively, by using the Michaelis-Menten equation. Each point represents the mean ± 
S.E.M. of three monolayers. 
 
Fig. 2. Effects of various inhibitors on FITC-insulin uptake by RLE-6TN cells. (A) 
Cells were treated with various inhibitors as described under Materials and Methods. 
The uptake of FITC-insulin (20 g/ml) with or without (control) an inhibitor for 60 min 
was measured at 37C or 4C. The dotted line indicates the control level. (B) Effects of 
various concentrations of dynasore on FITC-insulin (20 g/ml) uptake. Specific uptake 
was estimated by subtracting the cell surface binding at 4C from the total cell 
association at 37C. Each point represents the mean ± S.E.M. of three monolayers. 
**P<0.01, significantly different from each control. 
 
Fig. 3. Transport of intracellular FITC-insulin to the basal side of RLE-6TN monolayers. 
(A) Cells preloaded with FITC-insulin for 60 min were incubated with PBS-G buffer in 
the absence of FITC-insulin for a specified period. The amount of FITC-insulin 
transported to the basal side was measured. (B) The intactness of transported 
FITC-insulin was evaluated with a fluoroimage analyzer after separation by SDS-PAGE. 
(C) The amount of FITC-insulin remaining in the cells was measured after incubation 
with PBS-G buffer for 2.5 hr. Each point represents the mean ± S.E.M. of three 
monolayers. **P<0.01, significantly different from that at 0 hr. 
 
Fig. 4. Intracellular localization of FITC-insulin. RLE-6TN cells were observed by 
confocal laser scanning microscopy after incubation with FITC-insulin (20 µg/ml), 
LysoTracker Red (75 nM), and Hoechst 33342 (10 µM) for 30 min at 37C (A, B, C) or 
4C (D). (A, D) FITC-insulin (green), (B) LysoTracker Red (red), and Hoechst 33342 
(blue). Colocalization of fluorescence derived from FITC-insulin and LysoTracker Red 
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is shown by a yellow color in C (merged). 
 
Fig. 5. Estimation of intact FITC-insulin in RLE-6TN cells. Cells preloaded with 
FITC-insulin for 60 min were incubated with PBS-G buffer in the absence of 
FITC-insulin for a specified period. (A) The intactness of FITC-insulin was evaluated 
with a fluoroimage analyzer after separation by SDS-PAGE. (B) The vertical axis 
shows the normal scale. (C) The vertical axis shows a logarithmic scale. Each point 
represents the mean ± S.E.M. of three monolayers. 
 
Fig. 6. Effects of megalin siRNA transfection on the expression levels of mRNA and 
protein in RLE-6TN cells. RLE-6TN cells were transfected with control or megalin 
siRNA for 48 hr. (A) The expression levels of megalin mRNA were measured by 
real-time PCR analysis. (B) The expression levels of megalin protein were measured by 
Western blot analysis. Each point represents the mean ± S.E.M. of three monolayers. 
*P<0.05 and **P<0.01, significantly different from each control. 
 
Fig. 7. Effects of megalin silencing on the uptake of [
3
H]gentamicin and FITC-insulin 
by RLE-6TN cells. RLE-6TN cells were transfected with control or megalin siRNA for 
48 hr. The uptake amount of [
3
H]gentamicin (A) or FITC-insulin (B) for 60 min was 
measured at 37C or 4C after transfection. Specific uptake was estimated by 
subtracting the cell surface binding at 4C from the total cell association at 37C. Each 
point represents the mean ± S.E.M. of three monolayers. *P<0.05, significantly different 
from each control. 
 
Fig. 8. Expression of insulin receptor (A) and effects of insulin receptor (IR) siRNA 
transfection on IR mRNA expression (B) and the uptake of FITC-insulin by RLE-6TN 
cells (C). (A) The expression levels of IR in RLE-6TN cells and primary cultured 
alveolar type II epithelial cells (AT II) were measured by RT-PCR analysis. (B) IR 
mRNA was measured after transfection of control or IR siRNA by real-time PCR. (C) 
Specific uptake of FITC-insulin was estimated in the cells transfected with control 
siRNA or IR siRNA. Each point represents the mean ± S.E.M. of six monolayers (B, C). 
*P<0.05, significantly different from each control.  
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